Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels
Abstract Cold atmospheric plasma (CAP) is a partially ionized gas that gains attention as a well‐tolerated cancer treatment that can enhance anti‐tumor immune responses, which are important for durable therapeutic effects. This review offers a comprehensive and critical summary on the current unders...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202205803 |
| _version_ | 1797870150824755200 |
|---|---|
| author | Milica Živanić Albert Espona‐Noguera Abraham Lin Cristina Canal |
| author_facet | Milica Živanić Albert Espona‐Noguera Abraham Lin Cristina Canal |
| author_sort | Milica Živanić |
| collection | DOAJ |
| description | Abstract Cold atmospheric plasma (CAP) is a partially ionized gas that gains attention as a well‐tolerated cancer treatment that can enhance anti‐tumor immune responses, which are important for durable therapeutic effects. This review offers a comprehensive and critical summary on the current understanding of mechanisms in which CAP can assist anti‐tumor immunity: induction of immunogenic cell death, oxidative post‐translational modifications of the tumor and its microenvironment, epigenetic regulation of aberrant gene expression, and enhancement of immune cell functions. This should provide a rationale for the effective and meaningful clinical implementation of CAP. As discussed here, despite its potential, CAP faces different clinical limitations associated with the current CAP treatment modalities: direct exposure of cancerous cells to plasma, and indirect treatment through injection of plasma‐treated liquids in the tumor. To this end, a novel modality is proposed: plasma‐treated hydrogels (PTHs) that can not only help overcome some of the clinical limitations but also offer a convenient platform for combining CAP with existing drugs to improve therapeutic responses and contribute to the clinical translation of CAP. Finally, by integrating expertise in biomaterials and plasma medicine, practical considerations and prospective for the development of PTHs are offered. |
| first_indexed | 2024-04-10T00:23:53Z |
| format | Article |
| id | doaj.art-117f1cef7ba24f628cd9b5a356cab16e |
| institution | Directory Open Access Journal |
| issn | 2198-3844 |
| language | English |
| last_indexed | 2024-04-10T00:23:53Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj.art-117f1cef7ba24f628cd9b5a356cab16e2023-03-15T13:19:15ZengWileyAdvanced Science2198-38442023-03-01108n/an/a10.1002/advs.202205803Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using HydrogelsMilica Živanić0Albert Espona‐Noguera1Abraham Lin2Cristina Canal3Biomaterials Biomechanics and Tissue Engineering Group Department of Materials Science and Engineering Escola d'Enginyeria Barcelona Est (EEBE) and Research Centre for Biomedical Engineering (CREB) Universitat Politècnica de Catalunya (UPC) c/Eduard Maristany 14 Barcelona 08019 SpainBiomaterials Biomechanics and Tissue Engineering Group Department of Materials Science and Engineering Escola d'Enginyeria Barcelona Est (EEBE) and Research Centre for Biomedical Engineering (CREB) Universitat Politècnica de Catalunya (UPC) c/Eduard Maristany 14 Barcelona 08019 SpainPlasma Lab for Applications in Sustainability and Medicine‐Antwerp (PLASMANT) Department of Chemistry University of Antwerp Universiteitsplein 1 Wilrijk‐Antwerp 2610 BelgiumBiomaterials Biomechanics and Tissue Engineering Group Department of Materials Science and Engineering Escola d'Enginyeria Barcelona Est (EEBE) and Research Centre for Biomedical Engineering (CREB) Universitat Politècnica de Catalunya (UPC) c/Eduard Maristany 14 Barcelona 08019 SpainAbstract Cold atmospheric plasma (CAP) is a partially ionized gas that gains attention as a well‐tolerated cancer treatment that can enhance anti‐tumor immune responses, which are important for durable therapeutic effects. This review offers a comprehensive and critical summary on the current understanding of mechanisms in which CAP can assist anti‐tumor immunity: induction of immunogenic cell death, oxidative post‐translational modifications of the tumor and its microenvironment, epigenetic regulation of aberrant gene expression, and enhancement of immune cell functions. This should provide a rationale for the effective and meaningful clinical implementation of CAP. As discussed here, despite its potential, CAP faces different clinical limitations associated with the current CAP treatment modalities: direct exposure of cancerous cells to plasma, and indirect treatment through injection of plasma‐treated liquids in the tumor. To this end, a novel modality is proposed: plasma‐treated hydrogels (PTHs) that can not only help overcome some of the clinical limitations but also offer a convenient platform for combining CAP with existing drugs to improve therapeutic responses and contribute to the clinical translation of CAP. Finally, by integrating expertise in biomaterials and plasma medicine, practical considerations and prospective for the development of PTHs are offered.https://doi.org/10.1002/advs.202205803cancercold atmospheric plasmadrug deliveryhydrogelsimmunogenic cell deathimmunotherapy |
| spellingShingle | Milica Živanić Albert Espona‐Noguera Abraham Lin Cristina Canal Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels Advanced Science cancer cold atmospheric plasma drug delivery hydrogels immunogenic cell death immunotherapy |
| title | Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels |
| title_full | Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels |
| title_fullStr | Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels |
| title_full_unstemmed | Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels |
| title_short | Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels |
| title_sort | current state of cold atmospheric plasma and cancer immunity cycle therapeutic relevance and overcoming clinical limitations using hydrogels |
| topic | cancer cold atmospheric plasma drug delivery hydrogels immunogenic cell death immunotherapy |
| url | https://doi.org/10.1002/advs.202205803 |
| work_keys_str_mv | AT milicazivanic currentstateofcoldatmosphericplasmaandcancerimmunitycycletherapeuticrelevanceandovercomingclinicallimitationsusinghydrogels AT albertesponanoguera currentstateofcoldatmosphericplasmaandcancerimmunitycycletherapeuticrelevanceandovercomingclinicallimitationsusinghydrogels AT abrahamlin currentstateofcoldatmosphericplasmaandcancerimmunitycycletherapeuticrelevanceandovercomingclinicallimitationsusinghydrogels AT cristinacanal currentstateofcoldatmosphericplasmaandcancerimmunitycycletherapeuticrelevanceandovercomingclinicallimitationsusinghydrogels |